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Abstract
Background The topical corticosteroid halobetasol propionate (HP) and the retinoid tazarotene (TAZ) are effective in
psoriasis treatment. To mitigate adverse cutaneous reactions observed with monotherapy, a ﬁxed- combination HP
0.01%/TAZ 0.045% lotion has been developed for the treatment of plaque psoriasis in adults.
Objectives To investigate the long-term safety, efﬁcacy and maintenance of response with HP/TAZ lotion.
Methods This was a 1-year, multicentre, open-label study in 555 adults with psoriasis [Investigator’s Global Assessment (IGA) score of 3 (‘moderate’) or 4 (‘severe’) and body surface area (BSA) of 3–12% at baseline]. HP/TAZ was administered once daily for 8 weeks and then intermittently as needed in 4-week intervals for up to 1 year based on
achievement of treatment success [IGA score of 0 (‘clear’) or 1 (‘almost clear’)]. Maximum continuous exposure was
24 weeks.
Results Of 550 participants with postbaseline safety data, 318 (57.8%) achieved treatment success during the study.
Of those, 54.4% achieved treatment success within the ﬁrst 8 weeks; retreatment was not required for >4 weeks in over
half (55.3%), and 6.6% did not require any retreatment. Among participants enrolled for the full 52 weeks, 77.5% maintained BSA ≤5% on treatment. There were marked improvements in severity of itching, dryness and burning/stinging
over the study course. The most common treatment-related adverse events were application site reactions of dermatitis,
pruritus, pain and irritation.
Conclusions Fixed-combination HP/TAZ lotion provided maintained efﬁcacy with a favourable tolerability and safety
proﬁle, supporting its use for the long-term treatment and management of moderate-to-severe plaque psoriasis.
Received: 7 October 2020; Accepted: 16 December 2020
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Introduction
Topical corticosteroids (TCSs) are the mainstay of treatment for
psoriasis due to their anti-inflammatory properties. However,
they are limited by rebound effects upon sudden cessation of
treatment as well as tachyphylaxis and adverse cutaneous reactions with long-term use, including striae, telangiectasias and
skin atrophy.1–3 The superpotent TCS halobetasol propionate
(HP) has demonstrated superior efficacy over vehicle and other
TCSs as monotherapy for plaque psoriasis, though labelling
restrictions limit its use to 2–4 weeks of continuous treatment.4
Retinoids are a separate drug class that can treat psoriasis
through inhibition of keratinocyte proliferation, decreasing
expression of inflammatory markers, and normalizing keratinocyte differentiation. Tazarotene (TAZ) was the first topical
retinoid developed for the treatment of psoriasis,5 but may cause
cutaneous irritation when used alone.6
When used in combination, the anti-inflammatory properties
of TCSs may reduce TAZ-induced irritation, whereas TAZ can
mitigate corticosteroid safety concerns and increase the duration
of treatment effects.3,7,8 However, there are technical challenges
in creating a topical treatment that provides uniform and simultaneous disposition of multiple active ingredients onto the skin
in addition to efficient delivery into the dermal layers. A fixedcombination HP 0.01%/TAZ 0.045% lotion (HP/TAZ; Duobriiâ; Ortho Dermatologics, Bridgewater, NJ, USA) was recently
developed to treat psoriasis using a single formulation featuring
two active ingredients with different mechanisms of action. This
novel lotion formulation utilizes an innovative polymeric emulsion technology to provide uniform distribution of active ingredients and excipients onto the skin and to provide enhanced
epidermal barrier for improved skin moisturization.2 Application of fixed-combination HP/TAZ lotion results in higher permeation efficiency of the active ingredients compared with
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application of higher-dose HP or TAZ creams (alone or layered)2 and may provide synergistic efficacy beyond the additive
effects of the individual active ingredients.9
Two phase 3 studies demonstrated the efficacy and safety of
HP/TAZ lotion in the treatment of moderate-to-severe psoriasis.10–12 In these studies, participants received up to eight continuous weeks of treatment, with maintenance of effect observed
up to 4 weeks after treatment cessation. Here, we present the
results of a phase 3 open-label study assessing the long-term
safety, efficacy and maintenance of response of HP/TAZ lotion
in participants receiving up to 24 continuous weeks of treatment
and followed for up to 1 year.

Materials and methods
Study overview

This was a 1-year, multicentre, open-label study (NCT02462083)
in participants ≥18 years of age with plaque psoriasis. The study
was conducted in 45 study centres in the United States in accordance with ethical principles from the Declaration of Helsinki,
international conference on harmonization guidelines, good
clinical practice, and local regulatory requirements. The study
was reviewed and approved by the governing Institutional
Review Board (IRB) Schulman Associates IRB, Inc (Cincinnati,
OH, USA). Written informed consent was obtained prior to participation in the study.
Enrolment criteria

Participants were required to have a clinical diagnosis of moderate-to-severe plaque psoriasis, defined as an Investigator’s Global
Assessment (IGA) of 3 or 4, and body surface area (BSA) of 3–
12%; the face, scalp, palms, soles, axillae and intertriginous areas
were excluded from IGA and BSA assessments. Concurrent use
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of lithium or Plaquenil during the study was prohibited and participants were excluded for the following: use of any topical
antipsoriatic drug product within 14 days prior to baseline; use
of phototherapy, photochemotherapy, or non-biological systemic psoriasis therapy within 4 weeks prior to baseline; use of
biological therapies known to affect psoriasis within 3 months
of baseline; and prolonged exposure to natural or artificial
sources of ultraviolet radiation within 4 weeks prior to baseline.
Study design

All participants were treated with HP/TAZ lotion once daily for
8 weeks, with treatment used intermittently, as needed, in 4week intervals for the remainder of the 52-week study (Fig. 1).
At week 8, participants were evaluated for treatment success,
defined as IGA score of 0 or 1 (‘clear’ or ‘almost clear’). Those
who achieved treatment success stopped treatment for 4 weeks
and those who did not achieve treatment success continued
treatment for 4 weeks. All participants were re-evaluated at week
12 for improvement, defined as ≥1-grade improvement from
baseline IGA; those without improvement were discontinued
from the study, whereas those with improvement continued the
study and were subsequently managed in 4-week cycles (e.g.
treated with HP/TAZ lotion once daily for 4 weeks if they had
not achieved treatment success or receiving no treatment until
the next evaluation if they had achieved treatment success).
Maximum continuous exposure during the study was 24 weeks;
as such, if 24 weeks of continuous treatment had been received
at any point in the study, the participant needed an IGA score of
0 or 1 to continue the study. CeraVeâ hydrating cleanser and
CeraVeâ moisturizing lotion (L’Oreal, New York, NY, USA)
were provided for optional use as needed for optimal moisturizing/cleaning of the skin.

Analyses

The primary objective of the study was to evaluate safety and tolerability following long-term treatment with HP 0.01%/TAZ
0.045% lotion. The sample size selected for this study (approximately 500 enrolled, with the intent that ~300 participants
would be followed for 6 months and ~100 for 1 year) was
expected to provide sufficient data for a long-term safety evaluation of HP/TAZ lotion when used by adult subjects with plaque
psoriasis.
Adverse events (AEs) and serious AEs (SAEs) were classified
using terminology from the Medical Dictionary for Regulatory
Activities. Tolerability was evaluated at all study visits through
assessments of selected local signs and symptoms (itching, dryness and burning/stinging) and the presence or absence of significant known drug-related reactions (skin atrophy, striae,
telangiectasia and folliculitis). Any local skin reaction that
required the use of a concomitant therapy or was a cause for
study drug interruption or discontinuation was to be reported as
an AE. Efficacy was evaluated through IGA and BSA assessments.
All statistical processing was performed using SASâ. Descriptive
statistics were used to provide an overview of safety and efficacy
results; no imputations were made for missing data.

Results
Participant disposition and demographics

A total of 555 participants were treated with HP/TAZ during the
study. Of these, 503 (90.6%) completed 3 months on study, 391
(70.5%) completed 6 months on study and 138 (24.9%) completed 12 months on study. At week 12, only 26 participants
(4.7%) were discontinued from the study due to lack of efficacy,
defined as not having ≥1-grade improvement from baseline in

Evaluated for
Evaluated for No improvement
Treatment Successa Improvementb
Impr
at Week 8
at Week 12
ovem
ent

Discontinued
from study

Successa
Treatment stopped
for 4 weeks

Once-daily
HP/TAZ for
8 weeks
Screening
Day 0

No success
Continued
once-daily HP/TAZ
for 4 weeks

Week 8

Continued study and managed in 4-week cycles for up to 1 year, with participants
re-evaluated every 4 weeks for treatment successa
• Successa: Treatment stopped for 4 weeks
• No success: Continued once-daily HP/TAZ for 4 weeks

Week 12

Week 24

Week 52

If 24 weeks of continuous treatment were received at any point
in the study and the participant did not achieve an IGA score
of 0 or 1, the participant was discontinued from the study.

Figure 1 Open-label study design. aTreatment success deﬁned as score of 0 (clear) or 1 (almost clear) on IGA. bImprovement deﬁned as
≥1-grade improvement from baseline IGA. Maximum continuous exposure was 24 weeks. Each tick mark on the timeline indicates
4 weeks (timeline not to scale). HP/TAZ, halobetasol propionate 0.01%/tazarotene 0.045%; IGA, Investigator’s Global Assessment.
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IGA score. At week 24, 116 participants (20.9%) were discontinued from the study due to lack of efficacy – defined as 24 weeks
of continuous use without achieving an IGA of 0 or 1 – even
though all had at least a 1-grade improvement in IGA score from
baseline; through the end of the study, an additional nine participants (1.6%) were discontinued due to lack of efficacy. Subject
request (n = 87, 15.7%) was the other most common reason for
study discontinuation. A total of 33 participants (5.9%) discontinued the study due to an AE; AEs were deemed unrelated to
treatment in four of these participants.
Of all study participants, 550 had postbaseline safety data and
were included in the safety population. Mean age was 51.9 years
and the majority of participants were male, white and not Hispanic/Latino. Baseline IGA was moderate in most of the participants, and median BSA was 5% (Table 1). Median length of
study drug exposure was 172 days and the median number of
applications was 164.

Of 226 participants enrolled at least 8 weeks in the study and
who stopped therapy after achieving treatment success, 55.3%
did not require retreatment for at least 29 days (>4 weeks),
28.3% for at least 57 days (>8 weeks), and 19.5% for at least
84 days (>12 weeks); overall, 6.6% did not relapse and therefore
did not require any retreatment (Fig. 3).
Affected BSA decreased over time, from a median of 5.0% at
baseline (n = 550) to 4.0% at week 4 (n = 539), 3.0% at week 8
(n = 511) and 2.0% at week 16 (n = 418); a median BSA of
2.0% was maintained for the duration of the 52-week study. For
individuals participating for the full year, 77.5% maintained a
BSA level of ≤5% and 49.3% maintained a BSA level of ≤3%
during the study when on treatment (Fig. 4).
Treatment-emergent adverse events

A brief overview of safety data from this study has been previously presented.13 Over half of participants experienced treatment-emergent AEs (TEAEs) during the year-long study,

Efﬁcacy

Table 1 Participant demographic and baseline characteristics
(safety population)
HP/TAZ lotion
N = 550
Age, mean (range), year

51.9 (19–87)

Male

361 (65.6)

Female

189 (34.4)

Ethnicity, n (%)
Hispanic or Latino

141 (25.6)

Not Hispanic or Latino

409 (74.4)

Race, n (%)
473 (86.0)

Black or African American

46 (8.4)

Asian

15 (2.7)

Other†

16 (2.9)

IGA score, n (%)
3 – Moderate

476 (86.5)

4 – Severe

74 (13.5)

Affected BSA, %
Mean (SD)

5.6 (2.65)

Median (range)

5.0 (3–12)

BSA, body surface area; HP/TAZ, halobetasol propionate 0.01%/tazarotene
0.045%; IGA, Investigator’s Global Assessment; SD, standard deviation.
†Includes Native Hawaiian or Other Paciﬁc Islander (n = 3), American Indian
or Alaska Native (n = 1), and Other (n = 12).
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54.4% achieved
treatment success
within the first
75
69.8%
8 weeks

99.1%

99.4%

24

28

100.0%

85.2%
79.9%

54.4%

50
37.4%

25
12.6%

0
2

Sex, n (%)

White

100

Percentage of participants
(Cumulative)

Overall, 318 participants (57.8%) achieved treatment success at
some point during the study; the majority of these participants
(54.4%, n = 173) achieved treatment success within the
first 8 weeks (Fig. 2). In many participants, treatment success
was rapid, being achieved within the first 2 and 4 weeks in
12.6% and 37.4% of those who achieved treatment success,
respectively.

4

8

12

16

20

32

By Study Week

Figure 2 Time to ﬁrst treatment success in participants who
achieved treatment successa with HP/TAZ (n = 318). aFigure includes only participants who achieved treatment success, deﬁned
as score of 0 (clear) or 1 (almost clear) on IGA. Cumulative data
shown; as such, participants included in the bar graphs are not
mutually exclusive. N values for IGA assessments were as follows:
baseline n = 550; week 2 n = 544; week 4 n = 539; week 8
n = 511; week 12 n = 478; week 16 n = 419; week 20 n = 385;
week 24 n = 362; week 28 n = 261; week 32 n = 238. For the three
participants who achieved treatment success after week 24: one
participant did not have a week 24 visit and at the early termination
visit approximately 1 month later had an IGA of almost clear; one
participant stopped study treatment approximately 1 month after
week 24 and approximately 1 month later had an IGA of almost
clear; and one participant, who temporarily interrupted study drug
between weeks 20 and 24 due to a AE of contact dermatitis, had
an IGA of almost clear at the week 32 visit. HP/TAZ, halobetasol
propionate 0.01%/tazarotene 0.045%; IGA, Investigator’s Global
Assessment.
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Percentage of participants
(Cumulative)

100
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55.3%

40
28.3%
19.5%

20

12.4%

low rates of other application site disorders, including erosion
(1.6%), erythema (1.5%), rash (1.3%), reaction (0.9%), atrophy
(0.7%) and exfoliation (0.7%).
Overall, 7.5% of subjects discontinued due to TEAEs. Individual TEAEs that led to discontinuation in more than one participant each were application site dermatitis (n = 7), application
site pruritus (n = 7), application site pain (n = 6), application
site reaction (n = 5), psoriasis (n = 4), application site irritation
(n = 2) and application site urticaria (n = 2).

6.6%

Skin reactions
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Figure 3 Time to retreatment with HP/TAZ (n = 226a). aParticipants enrolled post 8 weeks in the study and who stopped therapy
after achieving treatment success [deﬁned as a score of 0 (clear) or
1 (almost clear) on IGA]. Cumulative data shown; as such, participants included in the bar graphs are not mutually exclusive. HP/
TAZ, halobetasol propionate 0.01%/tazarotene 0.045%; IGA,
Investigator’s Global Assessment.

≤5% BSA
≤3% BSA

Percentage of participants (%)

100

80

77.5%
71.5%

60
49.3%
39.7%

40

20

Discussion

0
Subjects participating for
at least 6 Months
(n = 390)

Subjects participating for
at least 1 Year
(n = 138)

Figure 4 Maintained BSAa from week 8 to end of study with HP/
TAZ. aOnly BSA records considered as occurring on treatment
were used in assessing if the percent BSA was maintained. BSA,
body surface area; HP/TAZ, halobetasol propionate 0.01%/tazarotene 0.045%.

primarily during the first 12 weeks (Table 2). Most TEAEs were
mild to moderate in severity and none of the serious AEs (SAEs)
were deemed related to treatment. The most common TEAEs
related to study drug were application site reactions of dermatitis, pruritus, pain and irritation (Table 2). Notably, there were
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Select local signs and symptoms showed marked improvements
in the severity of itching, dryness and burning/stinging over the
course of the study. The greatest improvement was for itching,
which was the most commonly reported symptom at baseline
(Fig. 5). Incidence of treatment-emergent Grade 3 (severe) local
skin reactions was 22.2% for itching, 6.9% for dryness and 9.8%
for burning/stinging.
Incidence of other local skin reactions is shown in Fig. 6 (data
shown for approximately every 12 weeks). Peak incidence
occurred at week 8 for both skin atrophy (2.3%) and folliculitis
(2.7%), and at week 28 for both striae and telangiectasias (1.5%
each). Most local skin reactions were transient and resolved
without interruption of the dosing regimen. Correlations
between treatment applications (timing and/or duration), frequency of local skin reactions and duration of local skin reactions could not be drawn. A local skin reaction was deemed an
AE if it required the use of a concomitant therapy or led to study
drug interruption or discontinuation. Local skin reactions most
frequently reported as AEs were application site folliculitis [14
participants (2.5%); one discontinued] and application site atrophy [four participants (0.7%); one discontinued]. No participant reported striae or telangiectasia AEs.

This 1-year, long-term and open-label study evaluated the efficacy and safety of a fixed-combination HP 0.01%/TAZ 0.45%
lotion as topical therapy for moderate-to-severe plaque psoriasis.
HP/TAZ lotion was developed to provide uniform delivery of
active ingredients at lower doses than the conventional
monotherapy formulations while providing enhanced hydration
and moisturization.2 In this study, HP/TAZ demonstrated rapid
and sustained treatment success with good tolerability and a
favourable safety profile, supporting the use of this lotion formulation in patients with an affected BSA of 3 to 12%.
Patient surveys have demonstrated that rapid improvement is
a primary concern among patients with psoriasis.14,15 The
majority of participants in this study achieved treatment success
over the course of this study; of those, over one-third (37.4%)
did so within 4 weeks and over half (54.4%) within 8 weeks of
initiating treatment. These results are consistent with findings
from two previous phase 3 trials of HP/TAZ lotion, in which
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Table 2 Treatment-emergent adverse event summary (safety population)
0–12 Weeks
(n = 527)

>12–24 Weeks
(n = 392)

>24–36 Weeks
(n = 239)

>36 Weeks
(n = 219)

Total
(N = 550)

Number of TEAEs

395

194

98

71

758

Participants with ≥1 TEAE, n (%)

223 (42.3)

130 (33.2)

61 (25.5)

43 (19.6)

314 (57.1)

Discontinued study drug due to TEAE, n (%)

30 (5.7)

9 (2.3)

2 (0.8)

0

41 (7.5)

Participants with ≥1 SAE,† n (%)

6 (1.1)

5 (1.3)

5 (2.1)

2 (0.9)

18 (3.3)

Treatment-related TEAE, n (%)

120 (22.8)

43 (11.0)

18 (7.5)

8 (3.7)

161 (29.3)

Mild

99 (18.8)

67 (17.1)

28 (11.7)

22 (10.0)

122 (22.2)

Moderate

101 (19.2)

55 (14.0)

26 (10.9)

16 (7.3)

151 (27.5)

Severe

23 (4.4)

8 (2.0)

7 (2.9)

5 (2.3)

41 (7.5)

Application site dermatitis

38 (7.2)

20 (5.1)

6 (2.5)

2 (0.9)

56 (10.2)

Application site pruritus

22 (4.2)

6 (1.5)

4 (1.7)

2 (0.9)

33 (6.0)

Application site pain

24 (4.6)

2 (0.5)

1 (0.4)

1 (0.5)

28 (5.1)

Application site irritation

10 (1.9)

4 (1.0)

3 (1.3)

1 (0.5)

13 (2.4)

TEAEs by maximum severity, n (%)

Most common treatment-related TEAEs,‡ n (%)

SAE, serious adverse event; TEAE, treatment-emergent adverse event.
†None of the SAEs were deemed related to treatment; ‡In >2% of total participants.
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Figure 5 Local skin reactions over time, by severity (safety population). Data not shown for all timepoints assessed. N values were as
follows: baseline n = 550; week 12 n = 480; week 24 n = 362; week 36 n = 227; week 52 n = 141.

over 40% of participants achieved treatment success by week
8.10,11 The rapid response to treatment with fixed-combination
HP/TAZ lotion may be due to the unique properties of its formulation. With polymeric emulsion technology, HP and TAZ
are encapsulated within oil droplets along with moisturizing and
hydrating ingredients, which are uniformly dispersed in an oil-
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in-water emulsion separated by a 3D mesh matrix. Upon skin
contact, the mesh immediately breaks apart, providing rapid and
uniform distribution of the active ingredients across the skin,
which allows for more efficient absorption than with the individual ingredients applied either alone or in layers.2 In in vitro studies, fixed-combination HP/TAZ lotion demonstrated >2-fold
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Figure 6 Incidence of local skin reactions over time (safety population). Data not shown for all timepoints assessed; incidence peaked
at week 8 for skin atrophy (2.3%) and folliculitis (2.7%), and at week 28 for both striae and telangiectasias (1.5% each). N values were as
follows: baseline n = 550; week 12 n = 480; week 24 n = 362; week 36 n = 227; week 52 n = 141.

and >1.5-fold increases in dermal tissue permeation of HP and
TAZ, respectively, over HP cream or TAZ cream individually. In
contrast, layering TAZ on top of HP decreased the permeation
of TAZ.2 Additionally, HP/TAZ lotion may provide synergistic
efficacy; depending on the measure used, HP/TAZ lotion was
27–44% more efficacious than what might have been expected
based on the individual efficacies of HP and TAZ. The mechanism for this improvement is not known, but may reflect the
combined anti-inflammatory properties of HP and TAZ.9
Maintenance of therapeutic effect is also important in psoriasis treatment. The efficacy of HP/TAZ lotion in this study was
maintained for over 1 month after treatment cessation in 55.3%
of participants who achieved treatment success. Further, almost
20% of treatment successes did not require retreatment for over
3 months and 6.6% required no retreatment at all. Decreases in
median BSA from 5.0% at baseline to 2.0% at week 16 were
maintained through week 52. Further, 40% of individuals participating at least 6 months in the study maintained ≤3% BSA
from week 8 to the end of the study when on treatment. These
maintenance results are consistent with an earlier study demonstrating that adding TAZ to once-daily TCS treatment resulted
in sustained improvements up to 12-weeks post-treatment compared with <4 weeks with twice-daily TCS treatment alone.8
TAZ may support the maintenance of corticosteroid treatment
efficacy by modulating abnormal differentiation and hyperproliferation of keratinocytes,16 which has been hypothesized to
restore skin to a quiescent, prelesional status.5
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A strength of the current study was the ability to evaluate
extended treatment with a superpotent TCS (up to 24 weeks of
continuous use) and long-term follow-up (up to 44-week posttreatment) in patients with psoriasis; this is notable given the
paucity of clinical trials investigating long-term (>6 months)
efficacy of TCSs.17 Further, to our knowledge, this is the first
study to assess a superpotent TCS for more than eight continuous weeks. As part of the study design, participants were discontinued due to protocol-defined lack of efficacy. Less than 5% of
participants were discontinued at week 12 (defined as no
improvement in baseline IGA) and 22.5% were discontinued at
or after week 24 (defined as 24 weeks of continuous treatment
and IGA score >1), even though all participants in the study
beyond 12 weeks experienced improvement in their psoriasis of
≥1 grade in IGA score. This unique study design feature may
have contributed to the 24.9% of participants that completed all
52 weeks on study; though the target completion rate was met,
it was lower than the approximately 50% rate observed in a 52week randomized study of calcipotriol/betamethasone dipropionate.18 However, the completion rate in our study was comparable to the 27% rate observed in a real-life, 52-week
observational effectiveness study of calcipotriol/betamethasone
dipropionate.19 An additional study design limitation is that
after 8 weeks of once-daily use of HP/TAZ lotion, participants
were required to halt treatment for at least 4 weeks upon treatment success, defined as achievement of ‘almost clear’ or ‘clear’
skin. If participants had been able to continue treatment until
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achieving clear skin, it is possible that time to retreatment would
have increased and that a greater proportion would not have
required any retreatment at all. Treatment to clear skin would
also better reflect the goals of both patients and clinicians in a
real-world setting, particularly given the low incidence of AEs
with up to 24 weeks of continuous use. Further analyses comparing participants who achieved clear vs. almost clear skin
would be beneficial to determine if treatment to clear confers
prolonged maintenance of effect.
Adverse events reported in this long-term study were consistent with the known safety profile of fixed-combination HP/
TAZ lotion. There were no new or late-onset safety concerns
emerging with prolonged treatment and none of the serious AEs
were considered related to treatment. The most common treatment-related AEs were application site reactions, similar to those
observed in the HP/TAZ pivotal phase 3 studies.10,11 Rates of
AEs and discontinuations due to TEAEs in this study were greatest in the first 12 weeks of HP/TAZ treatment and decreased
over time; AE rates were lowest after 36 weeks of treatment, with
individual TEAEs reported in two or fewer participants. Survey
data indicate that concerns about AEs from TCS use are common among both patients and clinicians,20,21 and contribute to
non-adherence in up to 28% of patients.20 As the study population after week 12 was enriched for participants that had
achieved IGA score improvement, these decreasing AE rates over
time suggest that treatment with HP/TAZ lotion may minimize
safety concerns for patients, potentially contributing to
improved long-term adherence.
No clinically meaningful trends in local skin reactions were
observed. For patients with psoriasis, skin atrophy is the AE of
greatest concern.20 Although atrophy is among the most common
adverse reactions associated with TCS therapy,22 the atrophogenic
potential of TCSs is reduced by combination with TAZ.23 In this
study, instances of atrophy with fixed-combination HP/TAZ
lotion were low, peaking at week 8 (2.3%) and declining through
study end; atrophy was reported as an AE in only four participants (0.7%) and led to only one discontinuation.

Conclusion
Fixed-combination HP/TAZ lotion has consistently demonstrated greater efficacy over placebo and may potentially provide
a synergistic benefit in the treatment of moderate-to-severe plaque psoriasis.9–11 The rapid and beneficial effects of HP/TAZ
lotion in this study were maintained in patients who achieved
clear or almost clear skin over 1 year of treatment and followup, with minimal safety concerns. These results support the use
of fixed-combination HP/TAZ lotion for the long-term treatment and management of moderate-to-severe plaque psoriasis.
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